Myriad Details Companion Dx Strategy for PARP, PTEN Inhibitors at Goldman Sachs Conference | GenomeWeb

Originally published June 29.

By Turna Ray

Amid economic pressures
dragging at Myriad Genetics' BRACAnalysis revenues, the diagnostics developer has recently been emphasizing to investors its strategic focus on companion diagnostics development with big pharma.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.